- Radionuclide targeted therapies (Lutitium-177-PSMA Therapy for Prostate Cancer, PRRT Dotatate Therapy for NET, RIT for lymphoma, thyrotoxicosis, bone metastases, thrombocytosis)
- PET/CT imaging
- SPECT, SPECT/CT imaging
- Diagnostic and therapeutic nuclear medicine
Dr Du has both a private and an NHS practice at The Royal Marsden.
Dr Yong Du graduated from Shandong Medical University. He was awarded a PhD in the University of Southampton for his work on radioimmunotherapy in lymphoma and completed full nuclear medicine specialist training at the Institute of Nuclear Medicine, University College Hospital in London. He was the first recipient of the national HEFCE Clinical Senior Lectureship Award in the Nuclear Medicine specialty (awarded in June 2009). He joined The Royal Marsden in February 2011 as a Consultant in Nuclear Medicine and PET/CT.
In conjunction with his clinical practice, he has research interests to further assess the role, efficacy and limitations of PET/CT in various cancers, so as to optimise its use and inform tailored treatments for individual patients.
Dr Yong Du has extensive experience in radionuclide targeted therapy. He leads the Radionuclide Therapy services at the Royal Marsden. He is interested in combining the fast advancing functional imaging technology with innovative therapeutic approaches to develop more effective radionuclide targeted therapy for patients. He pioneered the Lutitium-177-PSMA therapy for advanced prostate cancer patients in the UK and established the Lutinium-177-PSMA therapy service at the Royal Marsden Hospital, the first in a UK hospital.
In collaboration with researchers across the country, Dr Yong Du has led and contributed to a number of international and national studies. He has published first-authored research papers in high-impact oncology journals including Journal of Clinical Oncology, Blood and Cancer Research.
Dr Yong Du is a Trustee of the British Nuclear Medicine Society. He serves at a number of other international and national medical committees including the NCRI PET Research Network and the NCRI Clinical and Translational Radiotherapy (CTRad) Research Working Group.